Therefore, in this study, we compared the efficacy and safety of second‐ and third‐generation TKIs for NSCLC with uncommon EGFR mutations, which may provide new therapeutic options and strategies in clinical practice. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.